Status:
RECRUITING
The 5-FU Holter Study
Lead Sponsor:
University of Auckland, New Zealand
Collaborating Sponsors:
Gut Cancer Foundation
Auckland City Hospital
Conditions:
Gastrointestinal Malignancy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
To assess the feasibility of using ambulatory ECG monitoring (Holter monitor) for patients receiving 5-FU chemotherapy
Detailed Description
5-fluorouracil (5-FU) is the key chemotherapy component in systemic treatment of colorectal cancer. However, 5-FU treatment is also associated with cardiotoxicity which can have devastating consequenc...
Eligibility Criteria
Inclusion
- Patients with diagnosis of gastrointestinal malignancy
- Planned to receive either FOLFOX chemotherapy with any treatment intent
- Aged ≥ 18 years at time of signing informed consent form
Exclusion
- • ECG with left bundle branch block or left ventricular hypertrophy with strain
Key Trial Info
Start Date :
November 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2026
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06538610
Start Date
November 1 2024
End Date
January 1 2026
Last Update
December 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Auckland City Hospital
Auckland, New Zealand, 1023